{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:10:22Z","timestamp":1789783822410,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.eplepsyres.2004.09.005","type":"journal-article","created":{"date-parts":[[2005,1,7]],"date-time":"2005-01-07T18:04:19Z","timestamp":1105121059000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy and safety of levetiracetam 1000\u20133000 mg\/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study"],"prefix":"10.1016","volume":"63","author":[{"given":"Roy G.","family":"Beran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel F.","family":"Berkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gytis","family":"Danta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Hiersemenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham J.","family":"Schapel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.E.","family":"Vajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2004.09.005_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1059-1311(02)00292-3","article-title":"An open-label study of levetiracetam at individualised doses between 1000 and 3000mgday\u22121 in adult patients with refractory epilepsy","volume":"12","author":"Abou-Khalil","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"issue":"Suppl. 9","key":"10.1016\/j.eplepsyres.2004.09.005_bib4","first-page":"S16","article-title":"Monotherapy clinical trials of new antiepileptic drugs: design, indications, and controversies","volume":"38","author":"Chadwick","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib6","first-page":"489","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1157.1998.tb01278.x","article-title":"Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory","volume":"39","author":"Cramer","year":"1998","journal-title":"Epilepsia"},{"issue":"Suppl. 8","key":"10.1016\/j.eplepsyres.2004.09.005_bib8","first-page":"199","article-title":"Patient-rated priorities and relationship to distress in health-related quality of life domains: the QOLIE-31-P and QOLIE-10-P in a long-term levetiracetam study","volume":"43","author":"Cramer","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib9","unstructured":"Data on file. UCB Pharma, Braine-l\u2019Alleud, Belgium."},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib11","series-title":"Antiepileptic Drugs","first-page":"419","article-title":"Levetiracetam: mechanisms of action","author":"Margineanu","year":"2002"},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0920-1211(03)00080-9","article-title":"The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study","volume":"54","author":"Morrell","year":"2003","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(24)15285-3","article-title":"In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent","volume":"27","author":"Nicolas","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(95)00436-O","article-title":"The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes","volume":"286","author":"Noyer","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2004.09.005_bib17","first-page":"426","article-title":"A new antiepileptic drug. Levetiracetam, a pyrrolidone recently licensed as an antiepileptic drug","volume":"72","author":"Shorvon","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121104002384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121104002384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:14:27Z","timestamp":1760274867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121104002384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0920121104002384"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2004.09.005","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of levetiracetam 1000\u20133000mg\/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2004.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}